Pharmaceutical News Wrap Up: November 2014

Here at Simmons Hanly Conroy, our pharmaceutical lawyers understand the importance of staying up to date on the latest pharmaceutical news. Below is a list of some of the most recent headlines concerning U.S. Food and Drug Administration (FDA) recalls, approvals and warning label changes, medical studies and other pharmaceutical news taking place throughout the world.

  • Bleeding risk from blood thinner Pradaxa higher than first reported
    This Harvard editorial piece outlines the numerous studies that have linked Pradaxa to increased risk of a major bleed, which has caused dampened enthusiasm for the drug since its FDA approval in 2010.
  • Safety concerns slow sales of testosterone therapy
    Due to a one-year trial by the National Institutes of Health comparing men on a placebo versus men on testosterone, 2015 should shed some light on whether or not testosterone therapy benefits otherwise healthy men. These results could further affect the sales of testosterone medications.
  • Banned drugs still turning up in weight-loss supplements
    Despite FDA recalls for weight loss supplements containing dangerous substances, a study published recently found that two-thirds of the recalled products still contained banned substances. Manufacturers are continuing to produce and distribute the supplements even after FDA intervention.
Simmons Support Team
Simmons Hanly ConroyWritten by:

Editorial Team

The Simmons Hanly Conroy Editorial Team consists of journalists, writers and editors who strive to deliver accurate and useful information to families needing legal help. Our team works alongside the firm's attorneys and shareholders, as well as with medical professionals and other specialists, to keep all information relevant and helpful.

Topics

PAST ARTICLES